A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily for 12 Weeks for the Treatment of Opoid Induced Bowel Dysfunction in Adults Taking Opoid Therapy for Persistent Non-Cancer Pain